Piper Sandler maintains AbCellera Biologics at Overweight, raises price target to $20 from $12

Piper Sandler kept its Overweight rating on AbCellera Biologics and raised its price target to $20 from $12, citing a 74.1% upside from the Nov 13 close of $11.49.

Original reporting
Published Nov 16, 2026, 1:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Piper Sandler maintains AbCellera Biologics at Overweight, raises price target to $20 from $12 — source image
Decision brief

The 30-second read

$ABCLBullishMed
01

Why it matters

The target increase may prompt short covering and new buying, modestly boosting the stock.

02

Market read

Analyst upgrade provides a fresh catalyst for ABCL, offering a short‑term trading edge.

03

What to watch

No new clinical data released; price move relies solely on analyst opinion.

Relevance 7/10Novelty 6/10Timing: today

Background

AbCellera is a biotech firm developing antibody therapeutics; analyst coverage influences its valuation.

Company-level read

Ticker impact

$ABCLBullishMedium confidence
Context

Piper Sandler raised its price target on AbCellera Biologics to $20 from $12, indicating a bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The 66.7% target increase signals strong confidence, which can attract buying interest.

Market effects

Positive signal for the biotech sector may lift peer sentiment.

US biotech market may see modest gains.

Limited to investors tracking biotech equities.

Counterpoint

Target raise could be premature if upcoming trial data disappoints.

Key entities

  • Piper Sandler

    Raised price target on AbCellera.

Related articles

$ABCLMedAI 8/10

AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results

AbCellera Biologics (ABCL) plans to advance its hot-flash drug, ABCL635, into Phase 3 trials after promising Phase 2 results. The company is modeling dosing and engaging in regulatory discussions with the FDA. ABCL635 showed sleep-score results comparable to Bayer's LYNKUET, according to the company. AbCellera is also developing other candidates, including ABCL992, a longer-acting version of ABCL635.

$ABCLHighAI 9/10

AbCellera (ABCL) Q3 2026 Earnings Call Transcript

AbCellera (ABCL) reported Q3 2026 earnings, highlighting positive results for ABCL635 in treating women's health issues. The drug showed significant reduction in hot flashes and severity of symptoms compared to placebo. The company plans to advance ABCL635 into late-stage development in 2027 and is also exploring its use for cancer treatment-related hot flashes. Additionally, AbCellera announced a new program, ABCL992, and presented Phase I results for ABCL575.

$ABCLHighAI 9/10

AbCellera Q3 2026 slides: ABCL635 data sets new VMS efficacy bar

AbCellera (NASDAQ:ABCL) reported Q3 2026 results, highlighting positive Phase 2 data for ABCL635, its lead program for treating menopausal VMS. The company saw a net loss narrow to $41M and shares rose 5.22% to $12.50. ABCL635 showed significant efficacy in reducing VMS frequency and severity, with 37% of patients achieving complete symptom resolution. AbCellera plans to advance ABCL635 into late-stage trials in 2027 and expand into additional indications.

$ABCLHigh

AbCellera Reports Q3 2026 Business Results

AbCellera Biologics Inc. (ABCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. NEWS RELEASE AbCellera Reports Q3 2026 Business Results 11/9/2026 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2026. All financial information in this press release is reported in U.S. dollars,

$ABCLHighAI 9/10

AbCellera Reports Q3 2026 Business Results

AbCellera (ABCL) reported Q3 2026 results, with revenue up to $10.6M from $9.0M in Q3 2025. Net loss narrowed to $40.8M from $57.1M. The company raised $200M, bringing total liquidity to $890M. Positive Phase 2 data for ABCL635 and Phase 1 data for ABCL575 were announced, along with three new pipeline programs.